Methodological issues in studying the effect of the new oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) on absorption of iron.
Although deferoxamine is currently the drug of choice for iron chelation, there is more and more evidence of its toxicity. As a replacement for deferoxamine, 1,2-dimethyl-3-hydroxypyrid-4-one (L1), a new oral iron chelator, is undergoing clinical studies in thalassemic patients. Iron handling in experimental acute iron intoxication is being studied in a multiphase study. Preliminary results suggest that the L1-iron complex is not absorbed from the gastrointestinal tract. Methodological issues in studying iron chelation in the context of acute iron intoxication are presented.
Bentur
Y
Y
Division of Clinical Pharmacology & Toxicology, Hospital for Sick Children, Toronto, Ontario, Canada.
Klein
J
J
Levy
M
M
Olivieri
N
N
McGuigan
M
M
Koren
G
G
D000284:Administration, Oral; D000818:Animals; D015913:Chelation Therapy; D000077543:Deferiprone; D004285:Dogs; D007408:Intestinal Absorption / Q000187:drug effects*; D007501:Iron / Q000008:administration & dosage / Q000097:blood* / Q000378:metabolism; D011728:Pyridones / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors
D011728:Pyridones; D000077543:Deferiprone; D007501:Iron